Keppra

Levetiracetam, the active ingredient in Keppra, is an antiepileptic presented as an intravenous injection for intravenous use. It is indicated for the treatment of partial‑onset seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients requiring rapid seizure control, and is commonly employed in acute care settings such as emergency departments and intensive care units.

GNH USA supplies Keppra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and cold‑chain logistics where required.

Levetiracetam is an antiepileptic medication that reduces neuronal excitability across several seizure types, offering rapid control in acute settings. - Partial‑onset seizures: helps achieve seizure freedom or significant reduction in seizure frequency in patients with focal epilepsy. - Generalized tonic‑clonic seizures: provides control of convulsive episodes, decreasing the risk of injury and status epilepticus. - Myoclonic seizures: diminishes rapid muscle jerks, improving daily functioning and quality of life. - Adjunctive therapy: may be combined with other antiepileptic drugs to improve seizure control when monotherapy does not achieve desired outcomes.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias including neutropenia or thrombocytopenia - Suicidal thoughts or behavior - Severe depression or mood changes - Respiratory depression in vulnerable patients

When using levetiracetam, several precautionary measures should be observed to ensure safe therapy. - Renal impairment: assess function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and adjust if needed. - Pregnancy: risk unknown; use only if benefits outweigh potential risks. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Behavioral changes: observe for irritability, aggression, or mood swings. - Store at room temperature: keep in original packaging, protect from moisture and light.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require attention. Major Interactions (Avoid): - Co‑administration with other central nervous system depressants (e.g., barbiturates, opioids) may cause excessive sedation or respiratory depression. Moderate Interactions (Monitor Closely): - Strong enzyme inducers such as carbamazepine, phenytoin or phenobarbital can lower levetiracetam plasma levels. - Valproic acid may increase levetiracetam concentrations, requiring monitoring. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, advise alternative contraception. - Antifungal agents like fluconazole may modestly raise levetiracetam levels.